Please assess the completion status of the following clinical trial:

Trial Title: Atazanavir/r + Lamivudine Dual Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* HIV positive patients 18 years of age or older who signed an informed consent form~* Already on cART, without any treatment interruption.~* Treated with a cART regimen containing atazanavir boosted with ritonavir since at least 3 months~* With full virological suppression (VL\<50 copies/mL) for a minimum of six months and in at least in two consecutive determination 3 months +/-2 weeks apart from each other~* With CD4 cell count \>200 since at least 6 months and without opportunistic infections or other AIDS-related events since at least one year before screening~Exclusion Criteria:~* Previous virological failure on a lamivudine- or PI-containing regimen or previous exposure to lamivudine-containing suboptimal antiretroviral regimens~* Patients with at least a single viral load blip over 200 copies/mL~* Patients with M184V or major atazanavir resistance mutation at previous genotypic resistance test (historical genotype)~* Pregnancy or lactation, planned pregnancy in the short-term~* Patients with HBsAg positive chronic HBV infection~* Patients who experienced major toxicities related to any of the study drugs in the past~* Patients with grade 4 laboratory abnormalities at baseline (excluding lipid profile and plasma bilirubin concentration).~* Patients with non-AIDS related illnesses which could, in the Clinician's judgement, jeopardize the patient's compliance to the study procedures (i.e. Child-Pugh B or higher liver cirrhosis, active cancers on treatment...).~* Patients treated with proton-pump inhibitors or other concomitant medication with potential for interactions reducing exposure to atazanavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Switch (Type: EXPERIMENTAL): Switch to Atazanavir 300 mg with ritonavir 100 mg plus lamivudine 300 mg
- continue (Type: NO_INTERVENTION): Continue Atazanavir 300 mg with ritonavir 100 mg with the same NRTI backbone

Based on this trial design, predict the completion outcome and termination type (if applicable).